Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
245 Results for "
programmed
" in MedChemExpress (MCE) Product Catalog:
Products (245)
245 Results for "programmed" in MCE Product Catalog:
Cat. No.: HY-P990757
CAS No.: 2763222-58-6
Synonyms: ABL503, TJ-L14B
Target:
Research Areas:
Cat. No.: HY-P991113
CAS No.: 3002062-67-8
Synonyms: 609A
Target:
Research Areas:
Cat. No.: HY-P99639
CAS No.: 2348469-43-0
Synonyms: Genolimzumab; APL-501; CBT-501; GB-226
Target:
Research Areas:
Cat. No.: HY-151066
CAS No.: 2447065-99-6
Target:
Research Areas:
BMS-1233 is an orally active inhibitor for programmed cell death-ligand 1 (PD-L1), with IC50 of 14.5 nM. BMS-1233 promotes cell death of HepG2 in a Jurkat T cell and HepG2 cell co-culture model, exhibits antitumor activity against melanoma in mouse model .
Cat. No.: HY-P991151
CAS No.: 2923499-76-5
Synonyms: LBL-024
Target:
Research Areas:
Opamtistomig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human programmed death ligand 1 (PD-L1), CD274 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Opamtistomig is promising for research of various solid tumors and hematological malignancies .
Cat. No.: HY-147783
CAS No.: 2692652-36-9
Anticancer agent 68 is (Compound 12) is an anti-cancer agent. Anticancer agent 68 arrests the cells at the G2/M phase and induces programmed cell death. Anticancer agent 68 induces upregulation of tumor suppression via activation of p53 & PTEN .
Cat. No.: HY-144038
CAS No.: 2719736-43-1
DNA-PK-IN-5 is a potent inhibitor of DNA-PK. DNA-PK-IN-5 inhibits DNA-PKcs activity, thus greatly reducing tumor DNA repair and inducing cells to enter the apoptotic program. DNA-PK-IN-5 enhances the sensitivity of tumor tissues to radiotherapy, overcomes the problem of agent resistance, and enhances the inhibitory effect on a variety of solid tumors and hematological tumors (extracted from patent WO2021204111A1, compound 2) .
Cat. No.: HY-144039
CAS No.: 2711810-41-0
DNA-PK-IN-6 is a potent inhibitor of DNA-PK. DNA-PK-IN-6 inhibits DNA-PKcs activity, thus greatly reducing tumor DNA repair and inducing cells to enter the apoptotic program. DNA-PK-IN-6 enhances the sensitivity of tumor tissues to radiotherapy, overcomes the problem of agent resistance, and enhances the inhibitory effect on a variety of solid tumors and hematological tumors (extracted from patent WO2021197159A1, compound 6) .
Cat. No.: HY-157848
CAS No.: 924058-34-4
SARS-CoV-2-IN-82 (compound A) is a Programmed-1 ribosomal frameshift (-1 PRF) inhibitor of SARS-CoV-2 .
Cat. No.: HY-160542
CAS No.: 37162-93-9
Target:
Research Areas:
Clenhexyl hydrochloride is a urinary metabolite useful for quantitative screening in doping control screening programs .
Cat. No.: HY-158052
Target:
Research Areas:
PD-1/PD-L1 antagonist 1 (Compound A5) is an antagonist for programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) interaction, with an IC50 of 23.78 nM .
Cat. No.: HY-101097A
Target:
Research Areas:
PD-1-IN-17 TFA is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM .
Cat. No.: HY-P991148
CAS No.: 2983848-20-8
Target:
Research Areas:
Cat. No.: HY-152228
Target:
Research Areas:
Cat. No.: HY-101093B
Target:
Research Areas:
PD-1-IN-20 is the less active enantiomer of PD-1-IN-1. PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1) extracted from patent WO 2015033299 A1, compound example 4 .
Cat. No.: HY-187796
CAS No.: 2368183-94-0
Target:
Research Areas:
Lumipodlin is a programmed cell death ligand 1 (PD-L1) inhibitor. Lumipodlin is an antitumor agent that can be used in cancer-related research .
Cat. No.: HY-P991924
Cat. No.: HY-L162
3,860 compounds
Cell death plays a crucial role in the development of the body and the maintenance of internal balance to prevent the development of diseases. According to the regulation of the involved processes, cell death can be defined as programmed and non-programmed death. Programmed cell death (PCD) can be divided into lytic cell death and nonlytic cell death, mainly including apoptosis, necrotic apoptosis and Pyroptosis. Non-Programmed cell death (Non-PCD) generally refers to necrosis. In stark contrast to Accidental Cell Death (ACD), Regulatory Cell Death (RCD) relies on specialized molecular mechanisms. Cell death includes internal apoptosis, external apoptosis, necrotic apoptosis, ferroptosis, pyroptosis, lysosome-dependent cell death, etc.
MCE designs a unique collection of 3,860 cell death compounds, covering multiple targets, such as Apoptosis, Ferroptosis, Pyroptosis, Necroptosis, etc. It is a useful tool for screening cell death drugs.
Cat. No.: HY-P71191
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: PDCD4; Neoplastic Transformation Inhibitor Protein; programmed Cell Death 4; Nuclear Antigen H731; H731; Protein 197/15a; programmed Cell Death Protein 4; Nuclear Antigen H731-Like; programmed Cell Death 4 (Neoplastic Transformation Inhibitor)
Species:
Human
Source:
E. coli
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
